Treatment challenges in and outside a network setting: Head and neck cancers
Ester Orlandi(Fondazione IRCCS Istituto Nazionale dei Tumori), Andrea Tavilla, Ladislav Dušek(Institute of Health Information and Statistics), Christian Simon(University of Lausanne), Nadya Dimitrova(Istituto Superiore di Sanità), Margit Mägi(Universidad de Granada), Guido Mazzoleni, Patrick Arveux, Alice Nennecke, Jón G. Jónasson(Reykjavík University), Roberta De Angelis(Istituto Superiore di Sanità), Mario Šekerija(London Cancer), Marc Maynadié(Universidad de Granada), Pascale Grosclaude(Seoul National University Children's Hospital), Florence Molinié, Bernd Holleczek(Krebsregister Saarland), Lisa Licitra(University of Milan), Annalisa Trama(Fondazione IRCCS Istituto Nazionale dei Tumori), Diego Serraino(Centro di Riferimento Oncologico), Alain Monnereau, Sandra Mallone(Istituto Superiore di Sanità), Salvatore Alfieri(Fondazione IRCCS Istituto Nazionale dei Tumori), Maarit K. Leinonen(University of Helsinki), Véronique Bouvier(Inserm), Marc Colonna(Universidad de Granada), Anne‐Marie Bouvier(Inserm), Alessandr Barchielli, Nea Malila, Bénédicte Lapôtre-Ledoux(Chirurgie et extrémité céphalique, caractérisation morphologique et fonctionnelle), Monika Hackl(Universidad de Granada), Claire Schvartz, Gabriele Schubert-Fritschle, Jan Heidrich(Universidad de Granada), Anne-Sophie Woronoff, Roland Stabenow(Fondazione IRCCS Istituto Nazionale dei Tumori), Adriano Giacomin, Anne‐Valérie Guizard(Centre François Baclesse), Antonella Sutera Sardo, Jutta Engel, Brigitte Tretarre, Sabine Luttmann(Fondazione IRCCS Istituto Nazionale dei Tumori), Michel Velten(Pancreatic Cancer Action Network), Kris Henau, E. Van Eycken(Istituto Superiore di Sanità), Michel Robaszkiewic, Xavier Troussard, Kerri M. Clough‐Gorr(Boston University), Harry Comber(Universidad de Granada), Simona Bara, Isabelle Baldi(Pancreatic Cancer Action Network)
Cited by 40
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
|Oral Oncology|2018|802
The European cancer burden in 2020: Incidence and mortality estimates for 40 countries and 25 major cancers
|European Journal of Cancer|2021|650
Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet—a population-based study
|The Lancet Oncology|2017|510